Mondosanità reported on Thursday that immunotherapy can replace two cycles of chemotherapy in treating high-risk pediatric leukemia, with relapses nearly halved compared to standard treatment. The Ita
The reporting focuses on acute lymphoblastic leukemia, a blood cancer that affects children. According to the coverage, immunotherapy has been positioned as an alternative to part of the chemotherapy
Mondosanità's headline stated that relapses dropped by almost half when immunotherapy took the place of two chemotherapy cycles. The outlet did not provide the underlying trial data or patient numbers
Other Italian outlets covered the same development. ANSA reported that immunotherapy halves recurrences in pediatric acute leukemia, while Il Sole 24 ORE framed the news around high-risk cases specifi
The coverage did not specify which immunotherapy drug or protocol was involved, the age range of patients treated, or the location of the study. Those details were not included in the material availab
What to watch next: whether the full clinical data behind these figures is published, and whether regulators or treatment guidelines take up the approach for pediatric leukemia patients.
Mondosanità reports that immunotherapy can substitute two rounds of chemotherapy in high-risk pediatric leukemia, cuttin